Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Glycobiology

• Publication date

  2021-10-25

• Fields of study

  Medicine, Chemistry, Engineering

• Identifiers
  DOI 10.1093/glycob/cwab109PMID 34939096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Traces matter: Targeted optimization of monoclonal antibody N‐glycosylation based on/by implementing automated high‐throughput trace element screening

  2020cited by this paper
• Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations

  2020cited by this paper
• Protein Glycoengineering: An Approach for Improving Protein Properties

  2020cited by this paper
• Interaction analysis of glycoengineered antibodies with CD16a: a native mass spectrometry approach

  2020cited by this paper
• Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody

  2020cited by this paper
• A Detailed Protocol for Generation of Therapeutic Antibodies with Galactosylated Glycovariants at Laboratory Scale Using In-Vitro Glycoengineering Technology.

  2020cited by this paper
• Effects of sialic acid linkage on antibody-fragment crystallizable receptor binding and antibody dependent cytotoxicity depend on levels of fucosylation/bisecting.

  2019cited by this paper
• Generation of site‐distinct N‐glycan variants for in vitro bioactivity testing

  2019cited by this paper
• Impact of Fc N-glycan sialylation on IgG structure

  2019cited by this paper
• The History of IgG Glycosylation and Where We Are Now.

  2019cited by this paper
• Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms

  2018cited by this paper
• Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy

  2017cited by this paper
• Modulating IgG effector function by Fc glycan engineering

  2017cited by this paper
• Therapeutic monoclonal antibody N-glycosylation - Structure, function and therapeutic potential.

  2017cited by this paper
• Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development

  2017cited by this paper
• Impact of IgG Fc‐Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy

  2017cited by this paper
• Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life

  2016cited by this paper
• Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.

  2016cited by this paper
• Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans

  2016cited by this paper
• Two N-terminally truncated variants of human β-galactoside α2,6 sialyltransferase I with distinct properties for in vitro protein glycosylation.

  2016cited by this paper
• Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants

  2015cited by this paper
• In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity

  2015cited by this paper
• A common glycan structure on immunoglobulin G for enhancement of effector functions

  2015cited by this paper
• Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

  2015cited by this paper
• Fc glycans of therapeutic antibodies as critical quality attributes

  2015cited by this paper
• Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro

  2014cited by this paper
• With or Without Sugar? (A)glycosylation of Therapeutic Antibodies

  2013cited by this paper
• Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.

  2012cited by this paper
• Naturally occurring glycan forms of human immunoglobulins G1 and G2.

  2010cited by this paper

• Precision Glycoform Engineering: Combining plant and in vitro systems for tailored biopharmaceutical production

  2025cites this paper
• Recent progress in chemoenzymatic synthesis of human glycans.

  2024cites this paper
• Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics

  2023cites this paper
• Enzyme cascades for the synthesis of nucleotide sugars: Updates to recent production strategies.

  2022cites this paper